These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32667922)

  • 1. Perturbation biology links temporal protein changes to drug responses in a melanoma cell line.
    Nyman E; Stein RR; Jing X; Wang W; Marks B; Zervantonakis IK; Korkut A; Gauthier NP; Sander C
    PLoS Comput Biol; 2020 Jul; 16(7):e1007909. PubMed ID: 32667922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
    von der Heyde S; Bender C; Henjes F; Sonntag J; Korf U; Beißbarth T
    BMC Syst Biol; 2014 Jun; 8():75. PubMed ID: 24970389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
    Korkut A; Wang W; Demir E; Aksoy BA; Jing X; Molinelli EJ; Babur Ö; Bemis DL; Onur Sumer S; Solit DB; Pratilas CA; Sander C
    Elife; 2015 Aug; 4():. PubMed ID: 26284497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perturbation biology: inferring signaling networks in cellular systems.
    Molinelli EJ; Korkut A; Wang W; Miller ML; Gauthier NP; Jing X; Kaushik P; He Q; Mills G; Solit DB; Pratilas CA; Weigt M; Braunstein A; Pagnani A; Zecchina R; Sander C
    PLoS Comput Biol; 2013; 9(12):e1003290. PubMed ID: 24367245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
    Roller DG; Axelrod M; Capaldo BJ; Jensen K; Mackey A; Weber MJ; Gioeli D
    Mol Cancer Ther; 2012 Nov; 11(11):2505-15. PubMed ID: 22962324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.
    Zecena H; Tveit D; Wang Z; Farhat A; Panchal P; Liu J; Singh SJ; Sanghera A; Bainiwal A; Teo SY; Meyskens FL; Liu-Smith F; Filipp FV
    BMC Syst Biol; 2018 Apr; 12(1):33. PubMed ID: 29615030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
    Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
    Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
    J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model.
    Precazzini F; Pancher M; Gatto P; Tushe A; Adami V; Anelli V; Mione MC
    Dev Biol; 2020 Jan; 457(2):215-225. PubMed ID: 30998907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas.
    Ingels A; Dinhof C; Garg AD; Maddau L; Masi M; Evidente A; Berger W; Dejaegher B; Mathieu V
    Cancer Chemother Pharmacol; 2017 May; 79(5):971-983. PubMed ID: 28389780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
    Ishitsuka A; Fujine E; Mizutani Y; Tawada C; Kanoh H; Banno Y; Seishima M
    Int J Mol Med; 2014 Oct; 34(4):1169-74. PubMed ID: 25109763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feedback regulation in cell signalling: Lessons for cancer therapeutics.
    Nguyen LK; Kholodenko BN
    Semin Cell Dev Biol; 2016 Feb; 50():85-94. PubMed ID: 26481970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
    Meiler J; Guyot M; Hoffarth S; Wesarg E; Höhn Y; Breitenbuecher F; Schuler M
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1385-94. PubMed ID: 22488173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
    Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
    Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1-α dependent PDK-1 signaling pathway.
    Liu T; Jin L; Chen M; Zheng Z; Lu W; Fan W; Li L; Zheng F; Zhu Q; Qiu H; Liu J; Chen M; Tian C; Hu Z; Zhang C; Luo M; Li J; Kang T; Yang L; Li Y; Deng W
    Redox Biol; 2019 Jul; 25():101197. PubMed ID: 31023624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.